NEW YORK, NY / ACCESSWIRE / May 8, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided.
Eventbrite, Inc. (EB)
Class Period: Purchasers of shares (a) pursuant and/or traceable to the Company's September 2018 initial public offering; and/or (b) between September 20, 2018 and March 7, 2019
Lead Plaintiff Deadline: June 17, 2019
Join the action: https://www.zlk.com/pslra-1/eventbrite-inc-loss-form?prid=1435&wire=1
About the lawsuit: Eventbrite, Inc. allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: (1) the Company's migration of customers from Ticketfly to Eventbrite was progressing slower than expected; (2) as a result, the Ticketfly integration would take longer than expected; (3) as a result, the Company's revenue and growth would be negatively impacted; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
To learn more about the Eventbrite, Inc. class action contact email@example.com.
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Class Period: November 14, 2016 - February 28, 2019
Lead Plaintiff Deadline: May 13, 2019
Join the action: https://www.zlk.com/pslra-1/corbus-pharmaceutical-holdings-inc-loss-form?prid=1435&wire=1
About the lawsuit: During the class period, Corbus Pharmaceuticals Holdings, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Corbus improperly changed the primary efficacy endpoint for the clinical study of its drug candidate, Lenabasum, after the results were unblinded to Corbus; (2) Corbus reported a one-sided p value, not the traditional two-sided p value normally reported in clinical trials, in an effort to conceal the fact that the study results did not have statistical significance; and (3) as a result, Corbus' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To learn more about the Corbus Pharmaceuticals Holdings, Inc. class action contact firstname.lastname@example.org.
Nokia Corporation (NOK)
Class Period: April 15, 2015 - March 21, 2019
Lead Plaintiff Deadline: June 19, 2019
Join the action: https://www.zlk.com/pslra-1/nokia-corporation-loss-form?prid=1435&wire=1
About the lawsuit: Throughout the class period, Nokia Corporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Alcatel-Lucent S.A. ("Alcatel") maintained insufficient internal controls and was materially non-compliant in its business practices; (ii) Nokia had failed to conduct adequate due diligence into Alcatel prior to its acquisition; (iii) subsequent to the completion of Nokia's acquisition of Alcatel, the Company maintained insufficient internal controls over the integration of Alcatel's businesses; (iv) as a result of the foregoing, at all relevant times, Nokia was at risk of serious criminal and civil penalties; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more about the Nokia Corporation class action contact email@example.com.
You have until the lead plaintiff deadlines to request the court appoint as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: